- Home
- SEVN vs NBTX Comparison
SEVN vs NBTX Comparison
Compare SEVN & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- NBTX
- Stock Information
- Founded
- SEVN 1986
- NBTX 2003
- Country
- SEVN United States
- NBTX France
- Employees
- SEVN N/A
- NBTX 108
- Industry
- SEVN Real Estate Investment Trusts
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- NBTX Health Care
- Exchange
- SEVN Nasdaq
- NBTX Nasdaq
- Market Cap
- SEVN 167.7M
- NBTX 167.8M
- IPO Year
- SEVN N/A
- NBTX 2020
- Fundamental
- Price
- SEVN $11.66
- NBTX $3.33
- Analyst Decision
- SEVN Strong Buy
- NBTX Strong Buy
- Analyst Count
- SEVN 4
- NBTX 1
- Target Price
- SEVN $14.50
- NBTX $8.00
- AVG Volume (30 Days)
- SEVN 44.8K
- NBTX 7.6K
- Earning Date
- SEVN 04-28-2025
- NBTX 04-02-2025
- Dividend Yield
- SEVN 12.01%
- NBTX N/A
- EPS Growth
- SEVN N/A
- NBTX N/A
- EPS
- SEVN 1.15
- NBTX N/A
- Revenue
- SEVN $30,074,000.00
- NBTX N/A
- Revenue This Year
- SEVN $14.73
- NBTX N/A
- Revenue Next Year
- SEVN $5.39
- NBTX $221.06
- P/E Ratio
- SEVN $10.15
- NBTX N/A
- Revenue Growth
- SEVN N/A
- NBTX N/A
- 52 Week Low
- SEVN $10.18
- NBTX $2.76
- 52 Week High
- SEVN $14.66
- NBTX $7.51
- Technical
- Relative Strength Index (RSI)
- SEVN 48.10
- NBTX 49.44
- Support Level
- SEVN $11.48
- NBTX $3.26
- Resistance Level
- SEVN $11.91
- NBTX $3.65
- Average True Range (ATR)
- SEVN 0.34
- NBTX 0.20
- MACD
- SEVN 0.05
- NBTX 0.02
- Stochastic Oscillator
- SEVN 67.33
- NBTX 25.00
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.